Clinical implications of the DREAM Study

Affiliations

Comment

Mayer B Davidson. Diabetes Care. 2007 Feb.

. 2007 Feb;30(2):418-20.

doi: 10.2337/dc06-2051.

¹ Clinical Center for Research Excellence, Charles R. Drew University, 1731 East 120th St., Los Angeles, CA 90059, USA. mayerdavidson@cdrewu.edu

No abstract available

Comment in

Clinical implications of the DREAM study: response to Davidson.
Kanat M. Kanat M. Diabetes Care. 2007 May;30(5):e44; author reply e45. doi: 10.2337/dc07-0245. Diabetes Care. 2007. PMID: 17468372 No abstract available.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, et al. Lancet. 2006 Sep 23;368(9541):1096-105. doi: 10.1016/S0140-6736(06)69420-8. Lancet. 2006. PMID: 16997664 Clinical Trial.